ALC

Business Context and Reporting Period

Company: Alcon, Inc.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2007
Business Overview: Alcon is a global medical specialty company focused on eye care, developing, manufacturing, and marketing pharmaceuticals, surgical equipment/devices, and consumer eye care products. The company operates through two segments: Alcon United States and Alcon International. Products are sold in over 180 countries.

Key Financial Metrics (Year Ended Dec 31, 2007)

Material Changes vs. Prior Period

• Revenue Growth: Global sales increased 14.4% to $5.6 billion. Growth was driven by volume increases (11.0% in constant currency) and favorable foreign exchange fluctuations (3.4%). International sales grew 20.3%, outpacing U.S. sales growth of 8.5%.
• Profitability: Net earnings rose 17.7% to $1.6 billion. Operating income increased 19.8% to $1.9 billion, aided by reduced amortization expenses following significant impairment charges in 2006.
• Acquisition: On November 9, 2007, Alcon acquired a 77.4% controlling interest in WaveLight AG, a German refractive laser manufacturer, for approximately $113 million. This added $15.1 million in sales to the 2007 surgical segment.
• Impairment Charges: The company recorded $32.7 million in losses related to the impairment of refractive product line assets and inventory valuation in 2007, a decrease from the $144.8 million recorded in 2006.
• Dividends: Total dividends paid increased to $613.1 million (CHF 2.50 per share) from $417.0 million in 2006.

Guidance, Outlook, and Risks

• Tax Outlook: Management expects the consolidated effective tax rate for 2008 to be in the range of 13.5% to 14.5%, reflecting anticipated Swiss tax benefits from the relocation and expansion of global administration operations in Switzerland.
• Share Repurchase: In December 2007, the Board authorized a new program to purchase up to $1.1 billion of common shares, including a pro-rata purchase of shares from majority shareholder Nestlé. Purchases were expected to begin in the first half of 2008.
• Patent Litigation Risks: Significant risks exist regarding patent challenges from generic manufacturers for key products:
  • Vigamox: Litigation with Teva Pharmaceuticals regarding patent validity; judgment expected in H1 2009. A loss could allow generic competition before the 2020 patent expiration.
  • Patanol: Litigation with Apotex and Barr Laboratories regarding patent validity; trials scheduled for late 2008. A loss could allow generic competition as early as 2010.
• Product Lifecycle: The company anticipates a decline in sales and profits for TobraDex (patent expiration Jan 2009) and is pursuing approval for a replacement formulation, TobraDex ST.
• Regulatory Environment: The company faces ongoing pressure from government price controls and reimbursement policies in the U.S. (Medicare/Medicaid) and internationally (EU, Japan).

Investor Verification Checklist

• Patent Litigation Outcomes: Monitor the status and results of the Vigamox (Teva) and Patanol (Apotex/Barr) patent infringement trials, as adverse rulings could significantly impact future revenue streams.
• WaveLight Integration: Verify the successful integration of WaveLight AG's refractive laser technology and the transition of customers from Alcon's legacy LADARVision platform.
• TobraDex Replacement: Track the FDA approval status and market adoption of TobraDex ST to mitigate the impact of the 2009 patent expiration on the original TobraDex formulation.
• Share Repurchase Execution: Confirm the commencement and pace of the new $1.1 billion share repurchase program, particularly the pro-rata purchases from Nestlé.
• Effective Tax Rate: Validate the realization of the projected 13.5%–14.5% effective tax rate in 2008 based on the Swiss tax benefits and U.S. R&D credits.